Melatonin as a Potential Agent in the Treatment of Sarcopenia
AbstractConsidering the increased speed at which the world population is aging, sarcopenia could become an epidemic in this century. This condition currently has no means of prevention or treatment. Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms. This molecule has been implicated in a huge number of biological processes, from anticonvulsant properties in children to protective effects on the lung in chronic obstructive pulmonary disease. In this review, we summarize the data which suggest that melatonin may be beneficial in attenuating, reducing or preventing each of the symptoms that characterize sarcopenia. The findings are not limited to sarcopenia, but also apply to osteoporosis-related sarcopenia and to age-related neuromuscular junction dysfunction. Since melatonin has a high safety profile and is drastically reduced in advanced age, its potential utility in the treatment of sarcopenic patients and related dysfunctions should be considered. View Full-Text
Share & Cite This Article
Coto-Montes, A.; Boga, J.A.; Tan, D.X.; Reiter, R.J. Melatonin as a Potential Agent in the Treatment of Sarcopenia. Int. J. Mol. Sci. 2016, 17, 1771.
Coto-Montes A, Boga JA, Tan DX, Reiter RJ. Melatonin as a Potential Agent in the Treatment of Sarcopenia. International Journal of Molecular Sciences. 2016; 17(10):1771.Chicago/Turabian Style
Coto-Montes, Ana; Boga, Jose A.; Tan, Dun X.; Reiter, Russel J. 2016. "Melatonin as a Potential Agent in the Treatment of Sarcopenia." Int. J. Mol. Sci. 17, no. 10: 1771.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.